Neuronetics, Inc., based in Malvern, Pennsylvania, focuses on interventional mental health. Its NeuroStar Advanced Therapy system delivers noninvasive transcranial magnetic stimulation (TMS) cleared by the FDA for major depressive disorder and related conditions. The company also runs Greenbrook TMS, one of the larger clinic networks offering TMS and SPRAVATO therapies. STIM draws attention for its position in a sizable mental-health market that still has room to grow, alongside a services model that generates recurring revenue, even as the firm manages leverage and past net losses.
Over the last 30 days, STIM declined sharply. The stock closed at $2.01 on October 21, 2026, and has traded near $1.16 recently, marking a drop of approximately 42%. The move accelerated after the equity offering announcement, with trading volume rising well above average levels.
The three-month view shows even steeper weakness. The shares closed near $3.09 on August 20, 2026, after an earlier post-earnings lift above $3.30. The slide to roughly $1.16 equates to a decline of more than 60%, driven primarily by capital-structure issues rather than any deterioration in core operations.
The main trigger was the public offering announced on November 10, 2026. Neuronetics planned to sell 18.75 million shares at $1.60 each, a discount of about 20% to the prior close, plus an underwriter option for up to 2.8125 million more shares. Net proceeds were estimated at roughly $27.7 million, or $31.9 million if the option was exercised in full, with a portion slated to repay term loans under the Perceptive facility. The dilution and pricing weighed heavily on the shares.
Third-quarter results released on November 4, 2026, showed revenue up 12.5% year over year to $42.0 million, Greenbrook revenue rising 20.1% to $26.2 million, gross margin expanding to 52.2%, and adjusted EBITDA reaching a positive $1.9 million. Still, disclosures pointed to an expected revenue-covenant shortfall and ongoing going-concern questions. A sixth amendment to the Perceptive credit agreement on November 5 lowered certain covenants, contingent on a prepayment of at least $15 million by late November. Analyst price targets have stayed constructive, with a median near $6, yet the financing overhang dominated near-term sentiment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The broader quarterly drop highlights the ongoing contrast between operational improvement and balance-sheet strain. In the second half of 2026, Neuronetics has shifted toward NeuroStar capital sales, which management believes will support stronger net growth in 2027 even if sessions revenue moderates. Clinical efforts have also advanced, including a 510(k) submission for an accelerated TMS protocol in August and a November distribution agreement with Wave Neuroscience targeting PTSD. Persistent cash burn, high leverage, and covenant risks have nonetheless capped the stock’s upside. The November equity raise brought those concerns into sharper focus.
Several items stand out for investors. Revenue-covenant compliance and lender discussions will remain key, especially with the projected shortfall in March 2027. Full-year 2026 guidance calls for revenue of $160 million to $164 million and gross margin of 49% to 50%, so delivery against those figures will matter. The pace of the NeuroStar capital-sales transition and its impact on revenue mix will influence growth. Regulatory and partnership updates, such as the FDA 510(k) for accelerated TMS and the Wave Neuroscience PTSD work, could expand the market. Broader reimbursement trends and the company’s path to consistent cash generation will also shape how the market balances operational gains against remaining leverage. This article does not provide financial advice or forward-looking predictions.
In my own research process, I find Tickeron’s AI Trend Prediction Engine helpful for spotting longer-term directional signals across stocks like STIM. It processes historical patterns and market data to highlight potential trends, which can complement traditional fundamental review when evaluating names facing both operational progress and financing challenges.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
STIM saw its Momentum Indicator move below the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned negative. In 74 of the 81 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for STIM turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 31 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
STIM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STIM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for STIM entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +31.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where STIM advanced for three days, in 227 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
STIM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.178) is normal, around the industry mean (4.142). P/E Ratio (-5.000) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.250) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. STIM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STIM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of non-invasive therapies for psychiatric and neurological disorders
Industry MedicalNursingServices